| Management target | Revenue FY30 |
|---|
| Revenue growth | 13% YoY |
|---|---|
| Margins | Adjusted EBITDA margins improved to 19.4% from 18.2% YoY |
| Demand visibility | Strong; 550+ new patient registrations at North Bengaluru facility |
| Management confidence | High regarding oncology focus and market leadership |
Growth
Revenue grew 13% YoY to INR 6,951 Mn; PAT surged 190% YoY to INR 138 Mn.
Outlook
Targeting 1,000 bed addition by FY30 via 60% brownfield expansion and ~INR 5,500 Mn total capex.
Risks
Near-term margins impacted by North Bangalore startup losses (INR 70 Mn) and EPCG provisions.
Last quarter's promises, checked
Delivered
- Guided 15%+ revenue growth → delivered 13% (ex-fertility 13.4%) (= BEAT)
- Guided 20% EBITDA growth → delivered 20% (= BEAT)
- Launch North Bangalore by Q4 FY26 → operationalized May 2026 (= BEAT)
Partly delivered
- Guided 18.5% YTD EBITDA margin → delivered 19.4% in Q1 FY27 (= BEAT)
- Guided 5% ARPP growth → delivered 2% in current quarter (= MISS)
Investor Presentation filed with BSE, NSE: HCG. Summary written with AI assistance from the document.
Healthcare Global Enterprises Ltd: key numbers
- Share price
- ₹698.65
- Market cap
- ₹10,431 Cr
- Revenue (annual)
- ₹2,545 Cr
- Net profit (annual)
- ₹13.76 Cr
- P/E (TTM)
- 457.5×Sector 57.8×
- Promoter holding
- 64.21%+0.00% QoQ
- FII holding
- 2.73%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Healthcare Global Enterprises Ltd
All →Healthcare Global Enterprises Annual General Meeting
HealthCare Global Enterprises held its 28th Annual General Meeting on September 18, 2026, via video conferencing to transact business items listed in the notice.
Healthcare Global Enterprises Employee Stock Options
HealthCare Global Enterprises Limited granted 64,46,843 employee stock options under its ESOS 2026 scheme. The grant carries an exercise price of INR 495 per share.
Healthcare Global Enterprises Earnings Call Transcript: Key Takeaways
HCG reported a strong Q1FY27 with 13% YoY revenue growth and 20% EBITDA growth, driven by volume and improved payor mix.
Healthcare Global Enterprises Q1 FY27 Results: Net Profit ₹16.5 Cr, Up 175.0% YoY
Healthcare Global Enterprises Ltd reported revenue from operations of ₹693.4 Cr (+13.3% YoY) and net profit of ₹16.5 Cr (+175.0% YoY) for Q1 FY27.
- Key figure
- Net profit ₹16.5 Cr · +175.0% YoY
Healthcare Global Enterprises Earnings Call: Key Takeaways
HCG delivered strong FY26 performance with 15% revenue growth and margin expansion. Strategy focuses on oncology core through the sale of fertility unit Milann and brownfield expansion.
Healthcare Global Enterprises Earnings Call: Key Takeaways
HCG delivered strong FY26 results with 15% revenue growth and margin expansion to 18.5%, driven by operational leverage and clinical excellence.